These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9469350

  • 1. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT.
    J Clin Oncol; 1998 Feb; 16(2):616-21. PubMed ID: 9469350
    [Abstract] [Full Text] [Related]

  • 2. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [Abstract] [Full Text] [Related]

  • 3. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Goren MP, McKenna LM, Goodman TL.
    Cancer Chemother Pharmacol; 1997 Dec 01; 40(5):371-5. PubMed ID: 9272112
    [Abstract] [Full Text] [Related]

  • 4. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP, Epelman S, Bush DA.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):237-40. PubMed ID: 15184993
    [Abstract] [Full Text] [Related]

  • 5. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Sep 01; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 6. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct 01; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 7. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 8. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.
    Cancer; 2003 Jul 15; 98(2):331-6. PubMed ID: 12872353
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I, Keefe D, Myers M, Caruso D.
    Chemotherapy; 2005 May 15; 51(2-3):142-6. PubMed ID: 15886474
    [Abstract] [Full Text] [Related]

  • 10. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
    Manegold C, Drings P, Pawinski A, Lentz MA, van Glabbeke M, van Zandwijk N, Bachmann P, Schnaars Y, Skacel Z, Zatloukal P, Dolensky J, Jackevicius A, Petruzelka L, Giaccone G.
    Ann Oncol; 1996 Aug 15; 7(6):637-9. PubMed ID: 8879380
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA.
    J Clin Pharmacol; 1997 Jul 15; 37(7):618-24. PubMed ID: 9243355
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R.
    Clin Cancer Res; 2000 Apr 15; 6(4):1314-21. PubMed ID: 10778956
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE, Tessler J.
    Eur J Cancer Clin Oncol; 1983 Feb 15; 19(2):195-201. PubMed ID: 6402369
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
    Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN.
    Am J Clin Oncol; 1998 Aug 15; 21(4):413-5. PubMed ID: 9708645
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar 15; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.